OMEROS CORP Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate
OMEROS CORP (OMER) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 0.00% for the 12-month period ending 2018-12-31, per its 10-K filed 2019-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2019-03-01
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-09-30 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2013-06-30 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-09-30 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2012-06-30 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2018 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2017 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2016 was 0.00%.
- OMEROS CORP share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2015 was 0.00%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month |
|---|---|---|---|---|
| 2018-12-31 | 0.00% 10-K · filed 2019-03-01 | |||
| 2017-12-31 | 0.00% 10-K · filed 2019-03-01 | |||
| 2016-12-31 | 0.00% 10-K · filed 2019-03-01 | |||
| 2015-12-31 | 0.00% 10-K · filed 2018-03-01 | |||
| 2014-12-31 | 0.00% 10-K · filed 2017-03-16 | |||
| 2013-12-31 | 0.00% 10-K · filed 2016-03-15 | |||
| 2013-09-30 | 0.00% 10-Q · filed 2013-11-07 | 0.00% 10-Q · filed 2013-11-07 | ||
| 2013-06-30 | 0.00% 10-Q · filed 2013-08-09 | 0.00% 10-Q · filed 2013-08-09 | ||
| 2012-12-31 | 0.00% 10-K · filed 2015-03-16 | |||
| 2012-09-30 | 0.00% 10-Q · filed 2013-11-07 | 0.00% 10-Q · filed 2013-11-07 | ||
| 2012-06-30 | 0.00% 10-Q · filed 2013-08-09 | 0.00% 10-Q · filed 2013-08-09 | ||
| 2012-03-31 | 0.00% 10-Q · filed 2013-05-09 | |||
| 2011-12-31 | 0.00% 10-K · filed 2014-03-13 | |||
| 2011-09-30 | 0.00% 10-Q · filed 2012-11-09 | 0.00% 10-Q · filed 2012-11-09 | ||
| 2011-06-30 | 0.00% 10-Q · filed 2012-08-07 | 0.00% 10-Q · filed 2012-08-07 | ||
| 2010-12-31 | 0.00% 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |